Alaproclate
http://dbpedia.org/resource/Alaproclate an entity of type: Thing
Alaproclate (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.
rdf:langString
rdf:langString
Alaproclate
xsd:integer
5796854
xsd:integer
1118712273
rdf:langString
AB07
rdf:langString
N06
xsd:integer
13
xsd:integer
60719
xsd:integer
36591
xsd:integer
1997
xsd:integer
1
xsd:integer
18
xsd:integer
1
rdf:langString
D02787
rdf:langString
Uncontrolled
xsd:integer
1
xsd:integer
2
xsd:integer
2081
rdf:langString
Oral
rdf:langString
Clc1cccCCC
xsd:integer
1
rdf:langString
FZSPJBYOKQPKCD-UHFFFAOYSA-N
rdf:langString
C4R42570ZO
rdf:langString
changed
xsd:integer
477316338
rdf:langString
changed
rdf:langString
Alaproclate (developmental code name GEA-654) is a drug that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. In addition to its SSRI properties, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine.
xsd:nonNegativeInteger
4811
xsd:string
(hydrochloride)
xsd:string
60719-82-6
xsd:string
36591
xsd:string
C4R42570ZO
xsd:string
D02787
xsd:string
2081
